Amgen Inc.

AMGN

US0311621009

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

Pharmaceuticals

Calendar

02/05/2024 - Q1 2024 Earnings Release

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Amgen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

277.4 USD

Average target price

303.3 USD

Spread / Average Target

+9.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AMGEN INC.	-3.52%	149B
ELI LILLY AND COMPANY	+29.55%	699B
NOVO NORDISK A/S	+25.07%	571B
JOHNSON & JOHNSON	-4.48%	364B
MERCK & CO., INC.	+17.62%	326B
ABBVIE INC.	+3.64%	286B
ASTRAZENECA PLC	+14.68%	236B
NOVARTIS AG	+4.71%	198B
ROCHE HOLDING AG	-12.43%	194B
PFIZER, INC.	-3.73%	154B

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 01:41:21 03/05/2024 am IST			5-day change	1st Jan Change
275.5 ^USD	-0.67%		+3.16%	-3.52%

10:07pm	Earnings Flash (AMGN) AMGEN Reports Q1 EPS $3.96, vs. Street Est of $3.89	MT
10:07pm	Earnings Flash (AMGN) AMGEN Reports Q1 Revenue $7.45B, vs. Street Est of $7.453B	MT

Earnings Flash (AMGN) AMGEN Reports Q1 EPS $3.96, vs. Street Est of $3.89	01:37am	MT
Earnings Flash (AMGN) AMGEN Reports Q1 Revenue $7.45B, vs. Street Est of $7.453B	01:37am	MT
Amgen Guides For Full Year 2024 EPS of $19-$20.20 on Revenue of $32.5-$33.8 Billion, vs CIQ Analyst Consensus of $19.53/Share on Revenue of $32.9 Billion	01:35am	MT
Amgen first-quarter profit dips 1%, revenue rises 22%	01:31am	RE
Equity Markets Higher Ahead of Apple Earnings	01:22am	MT
S&P 500, Nasdaq Rise Intraday Amid Moderna Rally as Traders Await Apple Results	11:54pm	MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...	09:23pm
Stock Futures Gain Pre-Bell as Fed Leaves Key Rate Unchanged; Asia, Europe Churn	04:26pm	MT
European Midday Briefing : Stocks Steady as Powell Suggests Rate Hike Unlikely	02:34pm	DJ
Chimeric Therapeutics Appoints COO; Shares Rise 4%	06:08am	MT
Amgen investors await weight-loss drug data	01/05	RE
Amgen investors await weight-loss drug data	01/05	RE
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	30/04
Sector Update: Health Care Stocks Mixed Premarket Tuesday	30/04	MT
Amgen Reaches Deal to Resolve Patent Disputes With Sandoz	30/04	MT
Sandoz Reaches Agreement With Amgen Resolving All Patent Litigation	30/04	DJ
Sandoz Group Settles Patent Disputes with Amgen	30/04	MT
Wall Street: buoyed by Tesla, confident ahead of FOMC meeting	30/04	CF
Sandoz reaches agreement with Amgen over patent dispute	30/04	RE
Wall Street: buoyed by Tesla, confident ahead of FOMC meeting	30/04	CF
Earnings, Tech Outlooks Lift Wall Street Pre-Bell; Asia, Europe Up	29/04	MT
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe	26/04	MT
Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza	26/04	DJ
Amgen to Submits Marketing Authorization Application to the European Medicines Agency	26/04	CI
Wall Street: tech and SOXX in free fall this week	22/04	CF